Author (ref.) year
|
Country
|
CircRNA
|
Tumor type
|
Expression
|
Assay methods
|
Case
|
Cut-offvalue
|
Tumor stage
|
High level
|
Low level
|
Survival analysis
|
HR
|
95%CI
|
HR availability
|
Follow-up months
|
---|
Zhu [14] 2017
|
China
|
circ-BRAF
|
glioma
|
down-regulation
|
qRT-PCR
|
68
|
NA
|
grade(I-IV)
|
33
|
35
|
OS
|
4.13
|
1.79–9.56
|
K-M curve
|
60
|
Wang [15] 2018
|
China
|
circ-0001649
|
glioma
|
down-regulation
|
qRT-PCR
|
64
|
NA
|
grade(I-IV)
|
32
|
32
|
OS
|
2.012
|
1.012–4
|
Reported
|
60
|
Qu [16] 2019
|
China
|
circ-0079593
|
glioma
|
up-regulation
|
qRT-PCR
|
60
|
mean
|
grade(I-IV)
|
30
|
30
|
OS
|
2.21
|
1.023–4.772
|
Reported
|
60
|
Lv [17] 2020
|
China
|
circ-EPB41L5
|
GBM
|
down-regulation
|
qRT-PCR
|
45
|
median
|
grade (IV)
|
23
|
22
|
OS
|
3.401
|
1.388–8.88
|
Reported
|
45
|
Duan [18] 2018
|
China
|
circ-0074362
|
glioma
|
up-regulation
|
qRT-PCR
|
62
|
NA
|
grade(I-IV)
|
30
|
32
|
OS
|
2.695
|
1.054–6.897
|
Reported
|
56
|
Zhang [19] 2019
|
China
|
circ-0029426
|
glioma
|
up-regulation
|
qRT-PCR
|
59
|
mean
|
grade(I-IV)
|
31
|
28
|
OS
|
2.007
|
1.006–4.002
|
Reported
|
60
|
Yang [20] 2019
|
China
|
circ-POSTN
|
glioma
|
up-regulation
|
qRT-PCR
|
58
|
mean
|
grade(I-IV)
|
29
|
29
|
OS
|
2.1
|
0.74–5.91
|
K-M curve
|
60
|
Yang [21] 2019
|
China
|
circ-0034642
|
glioma
|
up-regulation
|
qRT-PCR
|
68
|
mean
|
grade(I-IV)
|
36
|
32
|
OS
|
1.75
|
0.84–3.63
|
K-M curve
|
60
|
Wang [22] 2019
|
China
|
circ-0005198
|
glioma
|
up-regulation
|
qRT-PCR
|
44
|
fold change
|
grade(I-IV)
|
22
|
22
|
OS
|
2.47
|
0.66–9.2
|
K-M curve
|
60
|
Meng [23] 2019
|
China
|
circ-SCAF11
|
glioma
|
up-regulation
|
qRT-PCR
|
40
|
NA
|
grade(I-IV)
|
20
|
20
|
OS
|
1.64
|
0.59–4.59
|
K-M curve
|
60
|
Lyu [10] 2020
|
China
|
circ-0013520
|
glioma
|
up-regulation
|
qRT-PCR
|
92
|
mean
|
grade(I-IV)
|
40
|
52
|
OS
|
1.85
|
0.98–3.48
|
K-M curve
|
31
|
Lyu [10] 2020
|
China
|
circ-0004379
|
glioma
|
up-regulation
|
qRT-PCR
|
92
|
mean
|
grade(I-IV)
|
42
|
50
|
OS
|
1.65
|
0.87–3.11
|
K-M curve
|
30
|
Lu [24] 2019
|
China
|
circ-0001730
|
glioma
|
up-regulation
|
qRT-PCR
|
99
|
NA
|
grade(I-IV)
|
49
|
50
|
OS
|
1.55
|
0.29–8.11
|
K-M curve
|
24
|
Liu [25] 2020
|
China
|
circ-CDC45
|
glioma
|
up-regulation
|
qRT-PCR
|
50
|
median
|
grade(I-IV)
|
25
|
25
|
OS
|
1.78
|
0.9–3.55
|
K-M curve
|
60
|
Ding [26] 2019
|
China
|
circ-NFIX
|
glioma
|
up-regulation
|
qRT-PCR
|
64
|
NA
|
grade(I-IV)
|
36
|
28
|
OS
|
0.87
|
0.17–4.46
|
K-M curve
|
60
|
Chen [27] 2018
|
China
|
circ-0000177
|
glioma
|
up-regulation
|
qRT-PCR
|
62
|
NA
|
grade(I-IV)
|
26
|
36
|
OS
|
2.05
|
0.52–8.1
|
K-M curve
|
60
|
Chen [28] 2020
|
China
|
circ-0074026
|
glioma
|
up-regulation
|
qRT-PCR
|
60
|
mean
|
grade(I-IV)
|
30
|
30
|
OS
|
2.6
|
1.37–4.94
|
K-M curve
|
60
|
Li [35] 2018
|
China
|
circ-ITCH
|
glioma
|
down-regulation
|
qRT-PCR
|
60
|
NA
|
grade(I-IV)
|
31
|
29
|
OS
|
2.326
|
1.204–5.431
|
Reported
|
80
|
Peng [36] 2019
|
China
|
circ-CPA4
|
glioma
|
up-regulation
|
qRT-PCR
|
73
|
average
|
grade(I-IV)
|
35
|
38
|
OS
|
3.98
|
1.23–12.94
|
K-M curve
|
42
|
- HR hazard ratio, CI Confidence interval, qRT-PCR quantitative reverse transcription-polymerase chain reaction, NA not available, OS overall survival, K-M Kaplan-Meier